BioSpace News Archive

The global controlled substance market was valued at ~US$ 64 Bn in 2018, and is projected to reach a value of US$ 115 Bn by 2027, expanding at a CAGR of 7% during the forecast period of 2021 to 2027.

According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027.

According to the report, the global Ophthalmic Drugs Market was valued at US$ 26.0 Bn in 2018 and is anticipated to expand at a CAGR of 4.1% from 2019 to 2030.

According to the report, the global organ preservation solution market was valued at US$ 193.4 Mn in 2018 and is projected to expand at a CAGR of 10.5% from 2019 to 2030.

The global organ transplant rejection medications market is expected to reach a value of ~US$ 6.3 Bn by the end of the forecast period.

According to the report, the global synthetic biology market was valued at US$ 4.96 Bn in 2018 and is projected to expand at a CAGR of 26.3% from 2019 to 2030.

The global psoriasis treatment market was valued at US$ 13.8 Bn in 2018, and is projected to expand at a CAGR of 11% from 2019 to 2027.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference.

Aadi Bioscience, Inc. (Nasdaq: AADI), today announced the commencement of dosing in PRECISION 1, a Phase 2 registrational trial of nab-sirolimus in patients 12 years and older with solid tumors with pathogenic inactivating alterations in TSC1 and TSC2 genes.

Windtree Therapeutics, Inc., a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that Craig Fraser, President and Chief Executive Officer, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.